Novo Nordisk AS’s shares plummeted by 27 after its obesity treatment failed to meet expectations in a key trial. The drug helped patients lose weight, but the results fell short of the predicted target. While the drug's results were similar to rival Eli Lilly & Co.’s Zepbound, Novo’s disappointment raised concerns about its position in the growing weight-loss market. The company plans further trials to boost the drug's effectiveness and expects regulatory approval by late 2025.